4.5 Review

The isoprostanes - Unique products of arachidonate peroxidation: Their role as mediators of oxidant stress

Journal

CURRENT PHARMACEUTICAL DESIGN
Volume 12, Issue 8, Pages 895-902

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161206776055985

Keywords

isoprostane; peroxidation; free radical; eicosanoid; thromboxane receptor

Funding

  1. NCI NIH HHS [CA77839] Funding Source: Medline
  2. NCRR NIH HHS [RR00095] Funding Source: Medline
  3. NIDDK NIH HHS [DK48831] Funding Source: Medline
  4. NIGMS NIH HHS [GM15431] Funding Source: Medline
  5. NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The isoprostanes (IsoPs) are a series of novel prostaglandin-like compounds formed in vivo in humans from the free radical-catalyzed peroxidation of arachidonate independent of the cyclooxygenase. While quantification of these compounds is a highly accurate measure of oxidant stress in vivo in humans. IsoPs also possess potent biological activity and likely mediate certain aspects of oxidative injury. The purpose of this review is to summarize selected aspects of our knowledge regarding the bioactivity of the IsoPs. I will first briefly highlight mechanisms involved in IsoP formation. Subsequently, I will discuss the biological activities of certain IsoPs that are formed in abundance in vivo and focus on two compounds, 15-F-2t-IsoP and 15-E-2t-IsoP, that have been Studied in the greatest detail. This review will then examine, at a molecular level, mechanisms by which IsoPs exert their bioactivity. It has been shown that they are ligands for various eicosanoid receptors, in particular, the thromboxane receptor. In addition, I will discuss the controversial evidence that a unique IsoP receptor(s) exists. Finally, I will offer avenues for future research related to the development of pharmacological approaches to modulate IsoP formation and action in vivo and thus decrease the pathophysiological sequelae of oxidative injury.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available